HER2-Positive Mucoepidermoid Breast Cancer With 61 Months Without Recurrence

Patient Info: Anonymized, female, 50s

Biomarkers: HER2-positive; ER low expression; PR-negative

She was alive without signs of recurrence after 61 months of follow-up, providing just over 5 years of documented follow-up for this second primary breast cancer.

PubMed CentralRead more →

Five Years Without Breast Cancer Recurrence Despite a Markedly Elevated CA 15-3

Patient Info: Anonymized, female, 70+ | Stage I

Biomarkers: ER-positive, PR-positive, HER2-positive

Five years after her Stage I breast-cancer diagnosis, breast imaging and systemic evaluation showed no evidence of recurrence. The markedly elevated CA 15-3 was traced to a separate renal tumor and normalized after nephrectomy.

PubMed CentralRead more →

Male Breast Cancer Controlled for Years Through Multiple Lines of Targeted and Endocrine Therapy

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: Initial tumor ER-positive, PR-positive, HER2-positive; later ER-positive, PR-negative, HER2-negative; PIK3CA mutation; germline BRCA1/2 negative

Metastatic Site: bones, pleura, liver

After a 5-year and 6-month disease-free interval, the cancer recurred in bone and later progressed to the pleura and liver. He died in January 2021, more than 13 years after his 2007 breast-cancer diagnosis.

PubMed CentralRead more →

Breast Cancer Patient Avoids a Potential Supplement Interaction During Paclitaxel Treatment

Patient Info: Anonymized, female, 50s

Biomarkers: ER-positive, PR-positive

She continued cancer treatment with trastuzumab after completing the documented paclitaxel portion of therapy.

PubMed CentralRead more →

Stage IV Breast Cancer: Sherri's Patient Story

Patient Info: Sherri, Female | Stage IV

Biomarkers: BRCA1-negative

Metastatic Site: Bone marrow

As of November 2023, Sherri had no evidence of disease on recent breast cancer scans but remained on targeted treatment every 3 weeks and had started oxaliplatin after surgery for a separate Stage III colon cancer.

The Patient StoryRead more →

Metastatic breast cancer: three years in remission with T-DM1 (Kadcyla) treatment

Patient Info: Anonymized, Female | Stage IV

Biomarkers: HER2-positive; hormone receptor-positive

Metastatic Site: liver; spine / bone

T-DM1 produced a complete clinical and radiological response after 7 cycles, sustained for 41 months and 60 cycles while treatment continued.

PubMed CentralRead more →

Stage IV HER2-Positive Multiple primaries: metastatic Breast Cancer + Colon/Colorectal Cancer: Sherri's Patient Story

Patient Info: Sherri, Female | Stage IV

Biomarkers: HER2-positive breast cancer; colon cancer Signatera positive before surgery and negative after surgery

Metastatic Site: Bone marrow

As of October 2023, Sherri had no evidence of disease on recent scans for HER2-positive metastatic breast cancer but was receiving oxaliplatin/Oxyplatin chemotherapy and transfusions for a separate early Stage III colon cancer.

The Patient StoryRead more →

Breast cancer lung metastasis treated with a minimally invasive freezing procedure

Patient Info: Anonymized, Female | Stage IV

Biomarkers: HER2-positive; ER-negative

Metastatic Site: lungs

Follow-up PET/CT at 3, 6, 9 and 12 months after cryoablation showed no progression or new lesions without systemic therapy.

PubMed CentralRead more →

Stage IV HER2-Positive Inflammatory Breast Cancer: Olivia's Survivor Story

Patient Info: Olivia Franz, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Bones; distant lymph nodes

As of October 2023, Olivia continued to show no evidence of disease on scans while receiving maintenance trastuzumab and pertuzumab every 3 weeks and zoledronic acid every 3 months for bone health.

MD AndersonRead more →

Stage IV HER2-Positive Colorectal Cancer: Brian's Patient Story

Patient Info: Brian Beck, 50s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

Brian was receiving tucatinib plus trastuzumab on a clinical trial and was working full time 4.5 years after his Stage IV diagnosis.

HER2-Positive Acantholytic Squamous Breast Cancer Responds Completely to Preoperative Therapy

Patient Info: Anonymized, female

Biomarkers: HER2-positive; postoperative residual in-situ disease ER-positive and PR-positive

The invasive cancer achieved a pathologic complete response, and she had no recurrence or metastasis during 1.5 years of follow-up.

PubMed CentralRead more →

HER2-positive metastatic lung cancer treated with trastuzumab deruxtecan (Enhertu)

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ERBB2/HER2 copy-number gain of at least 20 copies; TP53 C242fs; CDK12 copy-number gain; tumour mutational burden 3.2 mutations/Mb

Metastatic Site: lungs / multiple pulmonary nodules

Trastuzumab deruxtecan reduced the pulmonary nodules by more than 50% at 3 months and produced a documented response lasting 13.8 months.

PubMed CentralRead more →

Stage IV HR-Positive Breast Cancer: Abigail's Patient Story

Patient Info: Abigail Myers, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: bones, brain

Abigail continued living with Stage IV metastatic breast cancer after about 8 years of multiple treatment lines, including therapy for bone and brain metastases.

Dana-FarberRead more →

HER2-positive breast cancer on hemodialysis: partial response to T-DM1 then no metabolically active disease

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: Hormone receptor-positive; HER2/neu-positive; E-cadherin-positive; Ki-67 55-60%; luminal B type

As of March 2023, after 12 total cycles of T-DM1 and modified radical mastectomy, PET-CT showed no metabolically active disease, and she continued endocrine therapy and dialysis.

PubMed CentralRead more →

Stage II HER2-Positive Invasive Ductal Carcinoma: Lanie's Patient Story

Patient Info: Lanie Jones, Female, Under 40 | Stage II

Biomarkers: HER2-positive; Li-Fraumeni syndrome / TP53 mutation; BRCA-negative

As of January 2023, Lanie was living with Li-Fraumeni syndrome after 5 cancer diagnoses and was on lifelong maintenance chemotherapy while advocating for genetic testing and specialized surveillance.

The Patient StoryRead more →

Metastatic Breast Cancer Treatment Caused Severe Circulation Problems in Her Fingers and Toes

Patient Info: Anonymized, Female | Stage IV

Biomarkers: HER2-positive; ER-negative; PR-negative

The digital ischaemia improved after gemcitabine was stopped, without revascularisation, debridement or amputation, although a small necrotic fingertip area persisted at 3 months. Metastatic breast cancer treatment continued with further systemic lines after progression.

PubMed CentralRead more →

Cancer in Accessory Breast Tissue Under Both Arms in a Man

Patient Info: Anonymized, Male

Biomarkers: Left tumor: HER2-positive by gene amplification; ER-negative; PR-negative; Ki-67 70%; p53 staining 80%

After surgery removed both accessory-breast cancers, he continued with adjuvant paclitaxel, trastuzumab and radiation.

PubMed CentralRead more →

Ovarian Cancer: Faye's Patient Story

Patient Info: Faye Belvin, Female

Faye was still receiving the trial combination and said the treatment was working and that she felt better than she had in the previous 2 years.

Stage II HER2-Positive Breast Cancer: María's Survivor Story

Patient Info: María Ángeles, Female | Stage II

Biomarkers: HER2-positive

As of March 2022, María Ángeles was 4 years from diagnosis after completing 14 chemotherapy sessions, mastectomy with immediate reconstruction, 21 radiation sessions, and trastuzumab for Stage II HER2-positive breast cancer.

HER2-positive metastatic gastric cancer responding to trastuzumab deruxtecan rechallenge

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

After trastuzumab deruxtecan was restarted, his symptoms improved after the first cycle and imaging showed tumor shrinkage after 3 cycles. He was still receiving treatment without progression at the latest follow-up.

PubMed CentralRead more →

Stage IV HER2-Positive Gastric Cancer: Bryan's Patient Story

Patient Info: Bryan Chagolla, Male, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

Bryan had a strong response to trastuzumab deruxtecan in 2021. He died on May 13, 2022, surrounded by loved ones.

Stage IV gastric cancer with low platelets managed so chemotherapy could continue — Case 2

Patient Info: Anonymized, female, 70+ | Stage IV

After partial splenic embolization, her platelet count recovered and thrombocytopenia did not recur. She was receiving second-line ramucirumab plus paclitaxel at the latest follow-up.

PubMed CentralRead more →

HER2-positive left breast cancer treated with trastuzumab and mastectomy

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2/CerbB2 strongly positive; BRCA1/2 negative for known pathogenic variants; FANCA variant of uncertain significance.

She remained alive, asymptomatic, and disease-free while undergoing annual surveillance after treatment for the left HER2-positive breast cancer.

PubMed CentralRead more →

Recovery from severe bowel and oesophageal complications after breast cancer chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-positive.

She regained independence after an 89-day hospital course, but breast surgery remained deferred three months after intensive-care discharge and tamoxifen was being used during recovery.

PubMed CentralRead more →